Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Cambridge Heart

This article was originally published in The Gray Sheet

Executive Summary

Cambridge Heart: Developer of the CH 2000 system files a registration statement with the Securities and Exchange Commission for an initial public offering of 3 mil. shares, expected to be priced between $11 and $13 per share. The company plans to offer 2.4 mil. shares in the U.S. and 600,000 shares in a concurrent international offering. Underwriters Goldman Sachs and Bear Stearns have an over-allotment option to purchase 450,000 additional shares. Proceeds from the offering will fund research and development, clinical trials, purchase of capital equipment, expansion of sales and marketing efforts, working capital and general corporate purposes, the company says.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel